{"id":"6502d572-fcc3-5990-8b8b-1baf62bc3d3e","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-thyroid-oxidized","predicate":"decreases_in_recorded_comparison","statement":"RA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"86b4df1a-970a-5e0f-ab77-fe41307c5dbe","mechanism_event_label":"RA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.","subject":{"id":"7b72544b-d534-5919-b070-cd5edce404d8","slug":"ra-oxidation-products","display_name":"Rosmarinic-acid auto-oxidation products, mixture unresolved","entity_type_key":"chemical_species"},"object":{"id":"e041337b-c496-5eba-9290-bc8466279855","slug":"human-tshr","display_name":"Human thyrotropin receptor / TSHR","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"86b4df1a-970a-5e0f-ab77-fe41307c5dbe","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-thyroid-oxidized-event","event_type":"experimental_observation","label":"RA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.","description":"### ra-thyroid-oxidized\n\nRA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.\nAcross eight active compounds, half-inhibition required products equivalent to 20–80 micrograms/mL starting compound. No RA-specific universal clinical threshold.\nModel and exposure: 1985 cell-free hormone-binding study; oxidation-product mixtures.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The active principles of plant extracts with antithyrotropic activity: oxidation products of derivatives of 3,4-dihydroxycinnamic acid. | 1985 | https://pubmed.ncbi.nlm.nih.gov/3987612/ | https://doi.org/10.1210/endo-116-5-1677 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7b72544b-d534-5919-b070-cd5edce404d8","slug":"ra-oxidation-products","display_name":"Rosmarinic-acid auto-oxidation products, mixture unresolved","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Auto-oxidized RA with bovine TSH","sequence_order":0,"notes":""},{"entity":{"id":"e041337b-c496-5eba-9290-bc8466279855","slug":"human-tshr","display_name":"Human thyrotropin receptor / TSHR","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"starting compound","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"eee708a0-a4ea-5489-b58c-e69029423bba","slug":"bovine-tsh","display_name":"Bovine thyrotropin","entity_type_key":"protein"},"role":"tested hormone","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Auto-oxidized RA with bovine TSH\", \"comparator\": \"Hormone without oxidized compound\", \"endpoint\": \"RA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"1985 cell-free hormone-binding study; oxidation-product mixtures.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The active principles of plant extracts with antithyrotropic activity: oxidation products of derivatives of 3,4-dihydroxycinnamic acid. | https://pubmed.ncbi.nlm.nih.gov/3987612/ | https://doi.org/10.1210/endo-116-5-1677","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-thyroid-oxidized; Across eight active compounds, half-inhibition required products equivalent to 20–80 micrograms/mL starting compound. No RA-specific universal clinical threshold.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"15055256-4bec-5c6a-b886-668bd27a4dc5","evidence_kind":"source_excerpt","locator":"Lines 494-500","start_line":494,"end_line":500,"excerpt":"### ra-thyroid-oxidized\n\nRA auto-oxidation products inhibited bovine-TSH binding to human thyroid membranes.\nAcross eight active compounds, half-inhibition required products equivalent to 20–80 micrograms/mL starting compound. No RA-specific universal clinical threshold.\nModel and exposure: 1985 cell-free hormone-binding study; oxidation-product mixtures.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The active principles of plant extracts with antithyrotropic activity: oxidation products of derivatives of 3,4-dihydroxycinnamic acid. | 1985 | https://pubmed.ncbi.nlm.nih.gov/3987612/ | https://doi.org/10.1210/endo-116-5-1677 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"1985 cell-free hormone-binding study; oxidation-product mixtures.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}